Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group.
about
Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosisA multi-center randomised controlled trial of gatifloxacin versus azithromycin for the treatment of uncomplicated typhoid fever in children and adults in VietnamNovel Conserved Genotypes Correspond to Antibiotic Resistance Phenotypes of E. coli Clinical IsolatesMaintaining fluoroquinolone class efficacy: review of influencing factors.An open randomized comparison of gatifloxacin versus cefixime for the treatment of uncomplicated enteric fever.Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding.Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones.Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactionsMechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus.Comparative mutant prevention concentrations of pradofloxacin and other veterinary fluoroquinolones indicate differing potentials in preventing selection of resistance.Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone.Molecular characterization of fluoroquinolone resistance in Mycobacterium tuberculosis: functional analysis of gyrA mutation at position 74.Specific patterns of gyrA mutations determine the resistance difference to ciprofloxacin and levofloxacin in Klebsiella pneumoniae and Escherichia coliContribution of the 8-methoxy group to the activity of gatifloxacin against type II topoisomerases of Streptococcus pneumoniae.Gatifloxacin versus ofloxacin for the treatment of uncomplicated enteric fever in Nepal: an open-label, randomized, controlled trialContributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli.Clinical implications of reduced susceptibility to fluoroquinolones in paediatric Shigella sonnei and Shigella flexneri infectionsA novel ciprofloxacin-resistant subclade of H58 Salmonella Typhi is associated with fluoroquinolone treatment failurePharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae.Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae.Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser(83) and Asp(87).Mutation in the DNA gyrase A Gene of Escherichia coli that expands the quinolone resistance-determining regionEnhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus.Selection and genetic characterization of Streptococcus pneumoniae mutants resistant to the des-F(6) quinolone BMS-284756.Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin.Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.Gatifloxacin versus chloramphenicol for uncomplicated enteric fever: an open-label, randomised, controlled trial.Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates.The alpha4 residues of human DNA topoisomerase IIalpha function in enzymatic activity and anticancer drug sensitivity.Comparison of in vitro activities of fluoroquinolone-like 2,4- and 1,3-diones.Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates.Fluoroquinolone and quinazolinedione activities against wild-type and gyrase mutant strains of Mycobacterium smegmatis.Lethality of quinolones against Mycobacterium smegmatis in the presence or absence of chloramphenicol.Propensity of fluoroquinolones with different moieties at position 8 to cause resistance development in clinical isolates of Streptococcus pneumoniae.Contribution of the C-8-methoxy group of gatifloxacin to inhibition of type II topoisomerases of Staphylococcus aureus.Novel approach for comparing the abilities of quinolones to restrict the emergence of resistant mutants during quinolone exposure.Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2,4-diones.The treatment of enteric fever.
P2860
Q28344614-EECA0984-A21E-4317-A171-E23D6C5D2F5AQ28472731-1A074EDD-D923-4982-A195-01175BA2F1E3Q28534076-08CBE693-401B-410D-AAC0-E906D804991AQ30310427-63677670-F210-4043-87D9-6450FAE039F9Q33288953-276D72A0-FB30-4923-9D2E-8B6FB72C7EEAQ33556083-E680F506-BF1B-4D37-927D-8B89A362596CQ33805682-69F908FD-F824-4CCF-B55C-C5D9D4BB491BQ33980991-358C6A6B-B422-46DF-9A50-E039D9B0C553Q33983092-D7C33D46-53D7-4F07-8FE7-699045079F9BQ34077142-C2D65C2F-57D2-447B-A0A6-C14916DFAFE8Q34142238-48715C84-B297-4342-B4CF-CDBB92AF2353Q34529276-C32617DE-E126-448D-BDA2-0F1B23FBB4F7Q34538298-40870195-D9F4-46C3-B960-33B7985EE213Q34721556-3B470897-5738-423E-BEB9-C87DE2B2F6C9Q35055415-454A523F-1C6D-4EBF-B053-826C01F074FCQ36295431-DC887735-255B-45EB-BDF8-6831CA7F1790Q36551331-987A44C8-2BDE-4B10-9A03-6C45D971916CQ36723425-A80D3DAF-0D3E-4151-B52A-49830165A0D5Q37120372-EC5118B2-72D8-4F54-A462-76B6E22F1EFEQ39477371-D25B00D5-2580-4890-B69A-D9600D7FECAFQ39477717-201F433C-5D43-4F75-BEE2-7553C66F049CQ39478070-11ACAC86-5084-454D-A02E-A159DA2615C8Q39478440-68C06CB7-7D00-4864-B3A9-C4DEBDA6819FQ39478563-3D497C7D-4E45-4E1C-9344-113AAA432855Q39651272-48753CA4-6369-4D07-BB99-0C7097F77961Q39792565-90BA56AC-F07E-4B12-94EB-189A4A52BF08Q40326477-BD1B0AE4-D6F9-452E-9D7D-20C1427E1751Q40469459-01BF5EA9-A270-4D23-B2B0-51F1ED94A215Q40773283-5BCA5443-E75A-497B-9CD5-12A2723D918AQ42183775-1C4821C4-F1C8-4070-AB4A-D7A24FB46038Q42234726-36E49F0A-0827-47D4-9BBA-87DC7F7AE2E9Q42727166-17A32368-0509-4000-BA4F-2D4A48C26C97Q42727522-FF482044-1213-4316-B832-81F5520CB650Q42730708-146B7488-3AFB-40CC-BDE2-1301385ADE0AQ42784827-B7E05142-3334-446E-8838-9ACE66C6146CQ42947152-99C900E8-C086-4450-86CD-AE9D3E3FB848Q43251107-0BEC6CCE-6BD9-406F-B09E-4794BF14354EQ55465441-093BD137-F60E-44B2-8ECD-56232BBB992B
P2860
Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Gatifloxacin activity against ...... ties by the C-8-methoxy group.
@en
Gatifloxacin activity against ...... ties by the C-8-methoxy group.
@nl
type
label
Gatifloxacin activity against ...... ties by the C-8-methoxy group.
@en
Gatifloxacin activity against ...... ties by the C-8-methoxy group.
@nl
prefLabel
Gatifloxacin activity against ...... ties by the C-8-methoxy group.
@en
Gatifloxacin activity against ...... ties by the C-8-methoxy group.
@nl
P2093
P2860
P1476
Gatifloxacin activity against ...... ties by the C-8-methoxy group.
@en
P2093
P2860
P304
P407
P577
1999-12-01T00:00:00Z